Skip to main content
Mark Berger, MD, Cardiology, Philadelphia, PA, Pennsylvania Hospital

MarkDBergerMD

Cardiology Philadelphia, PA

Adult Congenital Heart Disease

Physician

Dr. Berger is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Berger's full profile

Already have an account?

Education & Training

  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemFellowship, Cardiovascular Disease, 1986 - 1989
  • UPMC Medical Education
    UPMC Medical EducationResidency, Internal Medicine, 1983 - 1986
  • University of Miami Leonard M. Miller School of Medicine
    University of Miami Leonard M. Miller School of MedicineClass of 1983

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 1984 - 2024
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification PrimeSUITE EHR, Greenway Health, LLC, 2012
  • Fellow (FACC) American College of Cardiology

Press Mentions

  • 100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AML
    100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AMLNovember 4th, 2020
  • Actinium Pharmaceuticals, Inc. Awarded Grant by National Institutes of Health to Study Novel Iomab-ACT Targeted Conditioning with a CD19 CAR T-cell Therapy
    Actinium Pharmaceuticals, Inc. Awarded Grant by National Institutes of Health to Study Novel Iomab-ACT Targeted Conditioning with a CD19 CAR T-cell TherapyOctober 21st, 2020
  • Actinium Pharmaceuticals to Host Webinar Focused on Actimab-A and Recent Developments Related to CD33 Targeted AML Therapies on July 13, 2017 at 8:00 Am ET
    Actinium Pharmaceuticals to Host Webinar Focused on Actimab-A and Recent Developments Related to CD33 Targeted AML Therapies on July 13, 2017 at 8:00 Am ETJuly 13th, 2017

Professional Memberships

Hospital Affiliations